Sells medicines for genetic diseases and develops additional drug candidates for patients with genetic conditions.
10-K for FY2025, filed Feb 24, 2026
BridgeBio sells medicines to specialty pharmacies and distributors, with revenue tied to their receipt of the product. It also earns license and service revenue and royalties from partners commercializing licensed products.
10-K for FY2025, filed Feb 24, 2026Net product revenue: Revenue is recognized when our customers, primarily specialty pharmacies and specialty distributors, obtain control of…View ↗
In 2025, Beyonttra contributed $105.0 million in license and services revenue following approvals in Europe and Japan. Additionally, we…View ↗
In February 2025, the European Commission approved acoramidis, under the brand name Beyonttra, for the treatment of adults with ATTR-CM in…View ↗
$502.1M
10-K for FY2025, filed Feb 24, 2026
$502.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
72%
FY2022: 2.0%
|
Net product revenue, FY2025
$362.4M Sources
|
Sold outright |
|
License and services revenue
|
26%
FY2022: 98%
|
License and services revenue, FY2025
$128.3M Sources
|
|
|
Royalty revenue
Licensed
|
2.3% |
Royalty revenue, FY2025
$11.4M Sources
|
Licensed |
Specialty pharmacies and specialty distributors buy the company’s medicines. Outside the United States, Bayer and Alexion commercialize Beyonttra under license; BridgeBio also commercializes it directly in certain international markets.
10-K for FY2025, filed Feb 24, 2026Net product revenue: Revenue is recognized when our customers, primarily specialty pharmacies and specialty distributors, obtain control of…View ↗
Our largest commercial product, acoramidis, was approved by the FDA in November 2024 for the treatment of transthyretin amyloid…View ↗
In February 2025, the European Commission approved acoramidis, under the brand name Beyonttra, for the treatment of adults with ATTR-CM in…View ↗
In March 2025, the Japanese Ministry of Health, Labor and Welfare approved acoramidis, under the brand name Beyonttra, for the treatment of…View ↗
No. It lost $724.9M in FY2025.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 31, 2026
Millions of people worldwide live with rare genetic conditions that have no approved treatment options because developing medicines for…View ↗
Growing. Revenue grew 7.2x in 4 years, from $69.7M in FY2021 to $502.1M in FY2025, about 64% a year.
Acquired a marketed product
The earlier report described acoramidis as under clinical development; the latest says BridgeBio markets it in the United States as Attruby after approval.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 24, 2026We are developing acoramidis, also known as AG10, an oral small molecule TTR stabilizer, for the treatment of TTR amyloidosis, or ATTR. A…View ↗
Our largest commercial product, acoramidis, was approved by the FDA in November 2024 for the treatment of transthyretin amyloid…View ↗
Oncology moved outside the core portfolio
The earlier report included a KRAS inhibitor portfolio for cancers; the latest describes BridgeBio Oncology Therapeutics as a separate spun-out company in which BridgeBio retains an equity interest.
Competes with Pfizer, Alnylam Pharmaceuticals, Ascendis Pharma, Tyra Biosciences, Ribomic, and BioMarin Pharmaceutical
10-K for FY2025, filed Feb 24, 2026Attruby/Beyonttra (acoramidis) for the treatment of adults with ATTR-CM competes with Vyndaqel / Vyndamax (tafamidis meglumine /…View ↗
Loading...